Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: strong gross margins and positive market access developments are offset by increased expenses and non-cash losses. The Q&A reveals some uncertainty, particularly regarding sales projections and treatment kit data. The company's strategic focus on trials and market expansion is promising, but lack of specific guidance tempers enthusiasm. Given these factors, the stock price is likely to remain stable in the short term.
Key Financial Performance
Revenue from cell therapy products $17.2 million, up 191% year-over-year. This growth was driven by the successful launch of Ryoncil in the final quarter of the year, with $13.2 million in gross sales and $11.3 million in reported net sales after a 14.6% gross-to-net adjustment.
Net operating cash spend $50 million, very similar to the prior year. This was despite investments in costs related to the commercial team build-out and activities around product launch.
Cash on hand $162 million (AUD 247 million) as of June 30, 2025.
Cost of revenues related to product sales $1.2 million, which is 10% of net product sales, resulting in a gross margin of 90%. Additionally, $3.9 million of expenses were related to non-cash amortization of the intangible value of prior MSC asset acquisition.
Selling, general and administrative expenses $39.3 million for FY 2025, an increase of $14.3 million year-over-year. This increase was related to the commercial team build and product launch.
Revaluation of contingent consideration A loss of $14.9 million in FY 2025, due to non-cash revaluation of potential future third-party payments.
Revaluation of warrant liability A loss of $5 million in FY 2025, compared to a gain of $0.8 million in FY 2024. This was due to FDA approval of Ryoncil and the consequential share price appreciation.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Ryoncil launch: Ryoncil, the first FDA-approved mesenchymal stromal cell therapy, was launched for pediatric steroid-refractory acute graft-versus-host disease (GvHD). It generated $13.2 million in gross sales and $11.3 million in net sales within its first quarter of availability.
Pipeline development: Two additional assets, remestemcel-L and rexlemestrocel-L, are in Phase III trials targeting inflammatory bowel disease, chronic heart failure, and chronic low back pain.
Market opportunity: Ryoncil's addressable market for pediatric and adult GvHD is $1 billion, while inflammatory bowel disease and chronic low back pain each represent over $10 billion in market opportunities.
Market expansion: Ryoncil has been adopted by 32 transplant centers in the U.S., with plans to onboard 45 centers covering 80% of pediatric bone marrow transplants. Medicaid coverage is now mandated across all states.
Revenue growth: Revenue from cell therapy products increased by 191% to $17.2 million, driven by Ryoncil's launch.
Cost management: Net operating cash spend remained stable at $50 million despite investments in commercial team build-out and product launch.
Label expansion: Plans to expand Ryoncil's label to adults with GvHD and initiate trials for inflammatory bowel disease.
Regulatory progress: Discussions with the FDA for accelerated approval of Revascor for chronic heart failure and confirmatory trials for rexlemestrocel-L in chronic low back pain are ongoing.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The company faces challenges in obtaining FDA approval for label expansion of Ryoncil to adults with GvHD and for other indications like inflammatory colitis. Regulatory requirements for confirmatory trials and chemistry, manufacturing, and controls (CMC) processes are significant hurdles.
Market Competition: The company operates in highly competitive markets, including treatments for inflammatory bowel disease, chronic low back pain, and heart failure. Competing therapies, including biologics and other advanced treatments, could limit market share.
Economic Uncertainties: The company’s financial performance is heavily reliant on the successful commercialization of Ryoncil and other pipeline products. Any economic downturns or changes in healthcare funding could adversely impact sales and operations.
Strategic Execution Risks: The company is investing heavily in clinical trials, product launches, and commercial team build-outs. Delays or failures in these areas could significantly impact financial performance and strategic objectives.
Supply Chain Disruptions: The company relies on specialized manufacturing processes for its mesenchymal stromal cell products. Any disruptions in the supply chain or manufacturing could delay product availability and impact revenue.
Financial Risks: The company reported a net operating cash spend of $50 million for the year, with significant investments in commercial activities. Sustained high expenses without proportional revenue growth could strain financial resources.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Ryoncil Label Expansion: The company plans to commence a registration trial for label expansion of Ryoncil in adults with steroid-refractory acute graft-versus-host disease (GvHD). This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN).
Inflammatory Colitis Study: A pivotal study for Ryoncil in medically-refractory inflammatory colitis is planned, focusing on early remission in patients with biologic-refractory inflammation.
Revascor Accelerated Approval: The company is preparing for an accelerated approval filing for Revascor, targeting chronic heart failure in adults with low ejection fraction. The FDA has indicated that the totality of trial results could support this pathway under the RMAT designation.
Rexlemestrocel-L for Chronic Low Back Pain: A confirmatory Phase III trial for rexlemestrocel-L in chronic low back pain is actively enrolling across multiple U.S. sites. The trial aims to confirm pain reduction at 12 months as the primary endpoint, with completion expected by the end of this year or the first quarter of next year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How long might it take for label expansion and to run the Phase III trial for Ryoncil in adults?
A:The objective is to commence an adult acute GvHD trial this quarter, working with the Bone Marrow Transplant CTN group. The trial will add Ryoncil on top of existing second-line agents like ruxolitinib for patients with severe disease. The study is expected to initiate this year, with specific dates and duration to be provided later.
Q:Can you provide more details on the Phase III chronic lower back pain trial?
A:The trial aims to address a significant unmet need by reducing or abolishing pain for 2-3 years with a single injection. Enrollment is ongoing at nearly 40 sites across the U.S., with adjustments made to the protocol design to improve enrollment. The trial is expected to complete enrollment by the end of the year or early next year, followed by a 12-month follow-up period to assess the primary endpoint of pain reduction.
Q:Are you able to disclose how many monthly treatment kits have been administered to date?
A:The company did not directly disclose the number of kits but mentioned that the information can be calculated based on the gross-to-net adjustments and the price per kit.
Q:How do you expect gross-to-net dynamics to evolve as the launch progresses?
A:Gross-to-net dynamics are expected to remain stagnant and flat, consistent with the current numbers.
Q:Will the adult GvHD trial include Jakafi-naive patients or only Jakafi-refractory patients?
A:The trial will not focus on Jakafi-refractory patients but will add Ryoncil on top of Jakafi for the largest possible market entry. The target is patients with severe disease (Grade C/D) where Jakafi alone has a 50% response rate.
Q:Are you planning to disclose more details from your FDA minutes regarding the adult study?
A:The company summarized its discussions with the FDA, stating alignment on using the product as early as possible in the most severe adult population. The trial will target patients with Grade C/D disease on Jakafi, aiming to increase the responder rate from 50% to 80% or more.
Q:What are the timelines and requirements for the IBD trial?
A:The trial design is being developed with input from key opinion leaders. It may involve both local and intravenous delivery of Ryoncil to achieve rapid remission in refractory patients. The company plans to update the market this quarter.
Q:Are all the kits being used for pediatric GvHD, or are they inclusive of other indications?
A:The company does not have specific data on how the kits are being used but believes they are predominantly used for pediatric acute GvHD. Some kits may also be used for other indications under compassionate care or physician discretion.
Q:How were the initial sales distributed over the period, and what revenue trajectory can be expected?
A:The company stated it is too early to provide projections, as only one quarter of sales has been reported. However, they expect continued strengthening of sales over the coming quarters.
Q:What feedback has the company received from the FDA regarding a filing in heart failure based on existing data?
A:The FDA has aligned with the company on manufacturing, potency assays, and the design of a confirmatory study involving 250-350 patients. The study will aim to reduce MACE events and mortality in high-risk patients.
Q:What work remains for market access in terms of Medicare and other payers?
A:The company has made excellent progress, with Ryoncil covered by insurance plans representing over 250 million lives. Medicaid coverage is in place in all states, and major commercial payers have issued favorable coverage policies. A specific J-Code for Ryoncil will go into effect on October 1, simplifying billing.
Q:Review of Unclear Management Responses
A:Management avoided directly disclosing the number of treatment kits administered, instead suggesting that the information could be calculated based on gross-to-net adjustments and kit pricing. Additionally, they did not provide specific revenue projections for the coming quarters, citing the early stage of sales reporting.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AUD detail
Advisory Executive
Bell
Chief Commercial
Co Research
Commercial Officer
Executive Mesoblast
FY increase
MSC
Officer Chief
Phase III
Research Division
Ryoncil FDA
Silviu
United States
announcement
asset
conference
extension
factor
generation technology
loss FY
market opportunity
opportunity product
platform technology
product launch
product portfolio
product sale
revaluation
revenue
slide snapshot
statement
technology generation
therapy product
view date
MESO Transcript
Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript
Unknown2-27
The company's financial performance shows improvement with increased revenue, reduced net loss, and better gross margin. However, the lack of specific strategic updates, regulatory hurdles, and negative cash flow from operations are concerns. The absence of shareholder return discussions and unclear management responses in the Q&A add uncertainty. Overall, the mixed signals suggest a neutral outlook.
Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript
Unknown8-29
The earnings call presents a mixed picture: strong gross margins and positive market access developments are offset by increased expenses and non-cash losses. The Q&A reveals some uncertainty, particularly regarding sales projections and treatment kit data. The company's strategic focus on trials and market expansion is promising, but lack of specific guidance tempers enthusiasm. Given these factors, the stock price is likely to remain stable in the short term.
Mesoblast Limited (NASDAQ:MESO) Q2 2025 Earnings Call Transcript
Positive3-3
The earnings call indicates strong financial metrics with a reduced net operating cash spend and positive revenue expectations from RYONCIL. Despite regulatory and competitive risks, the FDA approval and positive payer feedback are promising. The absence of a shareholder return plan is a slight drawback, but the overall sentiment is positive due to the product's market potential and the company's proactive approach to launching and expanding RYONCIL.
Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript
Unknown2-28
The company's earnings call reveals mixed signals: positive developments like increased enrollment sites for trials and positive payer feedback are offset by competitive pressures and significant financial losses. The Q&A section highlights positive payer feedback and rapid enrollment plans, but unclear timelines for FDA discussions raise concerns. The lack of a shareholder return plan and financial risks such as a substantial loss after tax further moderate the outlook. Given these factors, the stock price is likely to remain stable, leading to a neutral prediction.
MESO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
